Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease

 Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease

Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

Shots:

  • The two P-III MISSION AD1 and MISSION AD2 studies involves assessing of Elenbecestat (50mg) vs PBO in 2,100 patients with mild cognitive impairment or mild AD with confirmed amyloid pathology in the brain for 24mos.
  • The discontinuation is based on the Data Safety Monitoring Board (DSMB) recommendation due to its unfavorable risk-benefit ratio. Additionally, the P-II clinical study (Study 202) of Elenbecestat will also be discontinued
  • Elenbecestat (PO) is an investigational BACE inhibitor act by reducing amyloid plaque formations in the brain, thus slowing AD progression in the brain. The companies will continue to evaluate BAN2401 (beta-amyloid cleaving enzyme) in P-III CLARITY study

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post